Unknown

Dataset Information

0

Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.


ABSTRACT: Suvorexant is an orexin receptor antagonist approved for treating insomnia at a maximum dose of 20 mg. Phase-3 trials evaluated two age-adjusted (non-elderly/elderly) dose-regimes of 40/30 mg and 20/15 mg with the primary focus on 40/30 mg. We report here results from pooled analyses of the 20/15 mg dose-regime, which was evaluated as a secondary objective in the trials.Prespecified analysis of pooled data from two identical randomized, double-blind, placebo-controlled, parallel-group, 3-month trials in non-elderly (18-64 years) and elderly (? 65 years) patients with insomnia. Patients were randomized to suvorexant 20/15 mg (non-elderly/elderly), suvorexant 40/30 mg (non-elderly/elderly), or placebo; by design, fewer patients were randomized to 20/15 mg. Efficacy was assessed by self-reported and polysomnography (PSG; subset of patients) sleep maintenance and onset endpoints.Suvorexant 20/15 mg (N = 493 treated) was effective compared to placebo (N = 767 treated) on patient-reported and PSG sleep maintenance and onset endpoints at Night-1 (PSG endpoints) / Week-1 (subjective endpoints), Month-1 and Month-3, except for effects on PSG sleep onset at Month-3. Suvorexant 20/15 mg was generally well tolerated, with 3% of patients discontinuing due to adverse events over 3 months vs. 5.2% on placebo. Somnolence was the most common adverse event (6.7% vs. 3.3% for placebo). There was no systematic evidence of rebound or withdrawal signs or symptoms when suvorexant was discontinued after 3 months of nightly use.Suvorexant 20/15 mg improved sleep onset and maintenance over 3 months of nightly treatment and was generally safe and well tolerated.ClinicalTrials.gov trial registration numbers: NCT01097616, NCT01097629.

SUBMITTER: Herring WJ 

PROVIDER: S-EPMC4990943 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.

Herring W Joseph WJ   Connor Kathleen M KM   Snyder Ellen E   Snavely Duane B DB   Zhang Ying Y   Hutzelmann Jill J   Matzura-Wolfe Deborah D   Benca Ruth M RM   Krystal Andrew D AD   Walsh James K JK   Lines Christopher C   Roth Thomas T   Michelson David D  

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 20160915 9


<h4>Study objectives</h4>Suvorexant is an orexin receptor antagonist approved for treating insomnia at a maximum dose of 20 mg. Phase-3 trials evaluated two age-adjusted (non-elderly/elderly) dose-regimes of 40/30 mg and 20/15 mg with the primary focus on 40/30 mg. We report here results from pooled analyses of the 20/15 mg dose-regime, which was evaluated as a secondary objective in the trials.<h4>Methods</h4>Prespecified analysis of pooled data from two identical randomized, double-blind, plac  ...[more]

Similar Datasets

| S-EPMC4552781 | biostudies-literature
| S-EPMC5912319 | biostudies-literature
| S-EPMC5504309 | biostudies-literature
| S-EPMC5878201 | biostudies-literature
| S-EPMC4751744 | biostudies-literature
| S-EPMC3143155 | biostudies-literature
| S-EPMC4985567 | biostudies-literature
| S-EPMC5096011 | biostudies-literature
| S-EPMC6361524 | biostudies-literature
| S-EPMC9310640 | biostudies-literature